Antigen binding allosterically promotes Fc receptor recognition

References

• Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol. 2014;15:707–716. doi:10.1038/ni.2939.
   PubMed Web of Science ®Google Scholar
• Schroeder HW Jr., Cavacini L. 2010. Structure and function of immunoglobulins. J Allergy Clin Immunol. 125:S41–52. doi:10.1016/j.jaci.2009.09.046.
   PubMed Web of Science ®Google Scholar
• Mian IS, Bradwell AR, Olson AJ. Structure, function and properties of antibody binding sites. J Mol Biol. 217;1991:133–151.
   PubMed Web of Science ®Google Scholar
• Torres M, Casadevall A. 2008. The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol. 29:91–97. doi:10.1016/j.it.2007.11.004.
   PubMed Web of Science ®Google Scholar
• Keskin O. 2007. Binding induced conformational changes of proteins correlate with their intrinsic fluctuations: a case study of antibodies. BMC Struct Biol. 7:31. doi:10.1186/1472-6807-7-74.
   PubMed Web of Science ®Google Scholar
• Thielges MC, Zimmermann J, Yu W, Oda M, Romesberg FE. 2008. Exploring the energy landscape of antibody− antigen complexes: protein dynamics, flexibility, and molecular recognition. Biochemistry. 47:7237–7247. doi:10.1021/bi800374q.
   PubMed Web of Science ®Google Scholar
• Li T, Tracka MB, Uddin S, Casas-Finet J, Jacobs DJ, Livesay DR. 2014. Redistribution of flexibility in stabilizing antibody fragment mutants follows Le Chatelier’s principle. PLoS One. 9:e92870. doi:10.1371/journal.pone.0092870.
   PubMed Web of Science ®Google Scholar
• Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol. 2013;4:302. doi:10.3389/fimmu.2013.00302.
   Google Scholar
• Adachi M, Kurihara Y, Nojima H, Takeda‐Shitaka M, Kamiya K, Umeyama H. 2003. Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL–hyHEL‐10 complex. Protein Sci. 12:2125–2131. doi:10.1110/ps.03100803.
   PubMed Web of Science ®Google Scholar
• Li T, Tracka MB, Uddin S, Casas-Finet J, Jacobs DJ, Livesay DR. Can immunoglobulin C (H) 1 constant region domain modulate antigen binding affinity of antibodies?. J Clin Investig. 1996;98:2235. doi:10.1172/JCI119033.
   PubMed Web of Science ®Google Scholar
• Dam TK, Torres M, Brewer CF, Casadevall A. 2008. Isothermal titration calorimetry reveals differential binding thermodynamics of variable region-identical antibodies differing in constant region for a univalent ligand. J Biol Chem. 283:31366–31370. doi:10.1074/jbc.M806473200.
   PubMed Web of Science ®Google Scholar
• Tudor D, Yu H, Maupetit J, Drillet A-S, Bouceba T, Schwartz-Cornil I, Lopalco L, Tuffery P, Bomsel M. Isotype modulates epitope specificity, affinity, and antiviral activities of anti–HIV-1 human broadly neutralizing 2F5 antibody. Proceedings of the National Academy of Sciences 2012; 109:12680–12685. doi:10.1073/pnas.1200024109
   Google Scholar
• Li T, Tracka MB, Uddin S, Casas-Finet J, Jacobs DJ, Livesay DR. 2015. Rigidity emerges during antibody evolution in three distinct antibody systems: evidence from QSFR analysis of Fab fragments. PLoS Comput Biol. 11:e1004327. doi:10.1371/journal.pcbi.1004327.
   PubMed Web of Science ®Google Scholar
• Janda A, Bowen A, Greenspan NS, Casadevall A. 2016. Ig constant region effects on variable region structure and function. Front Microbiol. 7:22. doi:10.3389/fmicb.2016.00022.
   PubMed Web of Science ®Google Scholar
• Zhao J, Nussinov R, Ma B. Mechanisms of recognition of Abeta monomer, oligomer, and fibril by homologous antibodies. J Biol Chem. 2017. doi:10.1074/jbc.M117.801514.
   Web of Science ®Google Scholar
• Lua WH, Ling WL, Yeo JY, Poh JJ, Lane DP, Gan SKE. The effects of antibody engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: impact on antibody production and antigen-binding. Sci Rep. 2018;8:11110. doi:10.1038/s41598-017-18892-9.
   Google Scholar
• Sela-Culang I, Alon S, Ofran Y. 2012. A systematic comparison of free and bound antibodies reveals binding-related conformational changes. J Immunol. 189:4890–4899. doi:10.4049/jimmunol.1201493.
   PubMed Web of Science ®Google Scholar
• Ramadhany R, Hirai I, Sasaki T, Ono K, Ramasoota P, Ikuta K, Kurosu T. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection. Antiviral Res. 2015;124:61–68. doi:10.1016/j.antiviral.2015.10.012.
   PubMed Web of Science ®Google Scholar
• Jegaskanda S, Vanderven HA, Wheatley AK, Kent SJ. 2017. Fc or not Fc; that is the question: antibody Fc-receptor interactions are key to universal influenza vaccine design. Hum Vaccin Immunother. 13:1–9. doi:10.1080/21645515.2017.1290018.
   PubMed Web of Science ®Google Scholar
• Kellner C, Peipp M. 2014. Fc-optimized antibodies quickly pull the trigger. Blood. 124:3180–3181. doi:10.1182/blood-2014-10-602219.
   PubMed Web of Science ®Google Scholar
• Romain G, Senyukov V, Rey-Villamizar N, Merouane A, Kelton W, Liadi I, Mahendra A, Charab W, Georgiou G, Roysam B, et al. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood. 2014;124:3241–3249. doi:10.1182/blood-2014-04-569061.
   PubMed Web of Science ®Google Scholar
• Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity. 2017;46:577–586. doi:10.1016/j.immuni.2017.03.013.
   PubMed Web of Science ®Google Scholar
• Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 2007;67:8882–8890. doi:10.1158/0008-5472.CAN-07-0696.
   PubMed Web of Science ®Google Scholar
• Koerner SP, Andre MC, Leibold JS, Kousis PC, Kubler A, Pal M, Haen SP, Buhring HJ, Grosse-Hovest L, Jung G, et al. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia. Leukemia. 2017;31:459–469. doi:10.1038/leu.2016.194.
   PubMed Web of Science ®Google Scholar
• Frank M, Walker RC, Lanzilotta WN, Prestegard JH, Barb AW. 2014. Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J Mol Biol. 426:1799–1811. doi:10.1016/j.jmb.2014.01.011.
   PubMed Web of Science ®Google Scholar
• Zhang Y. 2015. Understanding the impact of Fc glycosylation on its conformational changes by molecular dynamics simulations and bioinformatics. Mol Biosyst. 11:3415–3424. doi:10.1039/c5mb00602c.
   PubMed Web of Science ®Google Scholar
• Buck PM, Kumar S, Singh SK. 2013. Consequences of glycan truncation on Fc structural integrity. MAbs. 5:904–916. doi:10.4161/mabs.26453.
   PubMed Web of Science ®Google Scholar
• Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, Koeleman CAM, Wuhrer M, van den Berg TK, Rispens T, et  al. Enhanced effector functions due to antibody defucosylation depend on the effector cell fcgamma receptor profile. J Immunol. 2017;199:204–211. doi:10.4049/jimmunol.1700116.
   Google Scholar
• Chen CL, Hsu JC, Lin CW, Wang CH, Tsai MH, Wu CY, Wong CH, Ma C. Crystal structure of a homogeneous IgG-Fc glycoform with the N-glycan designed to maximize the antibody dependent cellular cytotoxicity. ACS Chem Biol. 2017;12:1335–1345. doi:10.1021/acschembio.7b00140.
   PubMed Web of Science ®Google Scholar
• Li W, Yu R, Ma B, Yang Y, Jiao X, Liu Y, Cao H, Dong W, Liu L, Ma K, et al. Core fucosylation of IgG B cell receptor is required for antigen recognition and antibody production. J Immunol. 2015;194:2596–2606. doi:10.4049/jimmunol.1402678.
   PubMed Web of Science ®Google Scholar
• Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T, Barouch DH, Bailey-Kellogg C, Alter G, Ackerman ME. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. J Immunol Methods. 2017;443:33–44. doi:10.1016/j.jim.2017.01.010.
   PubMed Web of Science ®Google Scholar
• Bowen A, Casadevall A. 2016. Revisiting the immunoglobulin intramolecular signaling hypothesis. Trends Immunol. 37:721–723. doi:10.1016/j.it.2016.08.014.
   PubMed Web of Science ®Google Scholar
• Yang D, Kroe-Barrett R, Singh S, Roberts CJ, Laue TM. 2017. IgG cooperativity - Is there allostery? Implications for antibody functions and therapeutic antibody development. MAbs. 9:1231–1252. doi:10.1080/19420862.2017.1367074.
   PubMed Web of Science ®Google Scholar
• Ma B, Tsai CJ, Haliloglu T, Nussinov R. 2011. Dynamic allostery: linkers are not merely flexible. Structure. 19:907–917. doi:10.1016/j.str.2011.06.002.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang L, Tong H, Peng B, Rames MJ, Zhang S, Ren G. Corrigendum: 3D structural fluctuation of IgG1 antibody revealed by individual particle electron tomography. Sci Rep. 2016;6:17919. doi:10.1038/srep17919.
   PubMed Web of Science ®Google Scholar
• Sharp KA, O’Brien E, Kasinath V, Wand AJ. 2015. On the relationship between NMR-derived amide order parameters and protein backbone entropy changes. Proteins. 83:922–930. doi:10.1002/prot.24789.
   PubMed Web of Science ®Google Scholar
• Gunasekaran K, Ma B, Nussinov R. 2004. Is allostery an intrinsic property of all dynamic proteins? Proteins. 57:433–443. doi:10.1002/prot.20232.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Tsai CJ, Ma B. 2013. The underappreciated role of allostery in the cellular network. Annu Rev Biophys. 42:169–189. doi:10.1146/annurev-biophys-083012-130257.
   PubMed Web of Science ®Google Scholar
• Wei G, Xi W, Nussinov R, Ma B. Protein ensembles: how does nature harness thermodynamic fluctuations for life? The diverse functional roles of conformational ensembles in the cell. Chem Rev. 2016. doi:10.1021/acs.chemrev.5b00562.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Ma B, Tsai CJ. 2014. Multiple conformational selection and induced fit events take place in allosteric propagation. Biophys Chem. 186:22–30. doi:10.1016/j.bpc.2013.10.002.
   PubMed Web of Science ®Google Scholar
• Dai D, Huang Q, Nussinov R, Ma B. 2014. Promiscuous and specific recognition among ephrins and Eph receptors. Biochim Biophys Acta. 1844:1729–1740. doi:10.1016/j.bbapap.2014.07.002.
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Ma B, Nussinov R. 2009. Protein-protein interaction networks: how can a hub protein bind so many different partners? Trends Biochem Sci. 34:594–600. doi:10.1016/j.tibs.2009.07.007.
   PubMed Web of Science ®Google Scholar
• Keskin O, Gursoy A, Ma B, Nussinov R. 2008. Principles of protein-protein interactions: what are the preferred ways for proteins to interact? Chem Rev. 108:1225–1244. doi:10.1021/cr040409x.
   PubMed Web of Science ®Google Scholar
• Ma B, Shatsky M, Wolfson HJ, Nussinov R. 2002. Multiple diverse ligands binding at a single protein site: a matter of pre-existing populations. Protein Sci. 11:184–197. doi:10.1110/ps.21302.
   PubMed Web of Science ®Google Scholar
• Haliloglu T, Keskin O, Ma B, Nussinov R. 2005. How similar are protein folding and protein binding nuclei? Examination of vibrational motions of energy hot spots and conserved residues. Biophys J. 88:1552–1559. doi:10.1529/biophysj.104.051342.
   PubMed Web of Science ®Google Scholar
• Ma B, Tsai CJ, Nussinov R. 2000. A systematic study of the vibrational free energies of polypeptides in folded and random states. Biophys J. 79:2739–2753. doi:10.1016/S0006-3495(00)76513-1.
   PubMed Web of Science ®Google Scholar
• Ma B, Zhao J, Nussinov R. Conformational selection in amyloid-based immunotherapy: survey of crystal structures of antibody-amyloid complexes. Biochim Biophys Acta. 2016. doi:10.1016/j.bbagen.2016.05.040.
   Web of Science ®Google Scholar
• Srivastava A, Tracka MB, Uddin S, Casas-Finet J, Livesay DR, Jacobs DJ. 2016. Mutations in antibody fragments modulate allosteric response via hydrogen-bond network fluctuations. Biophys J. 110:1933–1942. doi:10.1016/j.bpj.2016.03.033.
   PubMed Web of Science ®Google Scholar
• Metzger H. The effect of antigen on antibodies: recent studies. Contemp Top Mol Immunol. 7;1978:119–152.
   PubMedGoogle Scholar
• Metzger H. Transmembrane signaling: the joy of aggregation. J Immunol. 149;1992:1477–1487.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Janda A. 2012. Immunoglobulin isotype influences affinity and specificity. Proc Natl Acad Sci U S A. 109:12272–12273. doi:10.1073/pnas.1209750109.
   PubMed Web of Science ®Google Scholar
• Zhao J, Nussinov R, Ma B. 2017. Allosteric control of antibody-prion recognition through oxidation of a disulfide bond between the CH and CL chains. Protein Eng Des Sel. 30:67–76. doi:10.1093/protein/gzw065.
   PubMed Web of Science ®Google Scholar
• Kortkhonjia E, Brandman R, Zhou JZ, Voelz VA, Chorny I, Kabakoff B, Patapoff TW, Dill KA, Swartz TE. Probing antibody internal dynamics with fluorescence anisotropy and molecular dynamics simulations. MAbs. 2013;5:306–322. doi:10.4161/mabs.23651.
   PubMed Web of Science ®Google Scholar
• Galanti M, Fanelli D, Piazza F. 2016. Conformation-controlled binding kinetics of antibodies. Sci Rep. 6:18976. doi:10.1038/srep18976.
   PubMed Web of Science ®Google Scholar
• Bongini L, Fanelli D, Piazza F, De Los Rios P, Sandin S, Skoglund U. 2004. Freezing immunoglobulins to see them move. Proc Natl Acad Sci U S A. 101:6466–6471. doi:10.1073/pnas.0400119101.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. 2014. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 5:520. doi:10.3389/fimmu.2014.00520.
   PubMed Web of Science ®Google Scholar
• Kiyoshi M, Caaveiro JM, Kawai T, Tashiro S, Ide T, Asaoka Y, Hatayama K, Tsumoto K. Structural basis for binding of human IgG1 to its high-affinity human receptor FcgammaRI. Nat Commun. 2015;6:6866. doi:10.1038/ncomms7866.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol. 177;2006:1129–1138.
   PubMed Web of Science ®Google Scholar
• Wang G, de Jong RN, van den Bremer ET, Beurskens FJ, Labrijn AF, Ugurlar D, Gros P, Schuurman J, Parren PW, Heck AJ. Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen. Mol Cell. 2016;63:135–145. doi:10.1016/j.molcel.2016.05.016.
   PubMed Web of Science ®Google Scholar
• Mimura Y, Sondermann P, Ghirlando R, Lund J, Young SP, Goodall M, Jefferis R. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem. 2001;276:45539–45547. doi:10.1074/jbc.M107478200.
   PubMed Web of Science ®Google Scholar
• Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. 2015. Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci U S A. 112:833–838. doi:10.1073/pnas.1418812112.
   PubMed Web of Science ®Google Scholar
• Lund J, Tanaka T, Takahashi N, Sarmay G, Arata Y, Jefferis R. A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation. Mol Immunol. 27;1990:1145–1153.
   PubMed Web of Science ®Google Scholar
• Walker MR, Lund J, Thompson KM, Jefferis R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J. 259;1989:347–353.
   PubMed Web of Science ®Google Scholar
• Jefferis R. The glycosylation of antibody molecules: functional significance. Glycoconj J. 10;1993:358–361.
   PubMed Web of Science ®Google Scholar
• Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol. 157;1996:4963–4969.
   PubMed Web of Science ®Google Scholar
• Yu X, Baruah K, Harvey DJ, Vasiljevic S, Alonzi DS, Song BD, Higgins MK, Bowden TA, Scanlan CN, Crispin M. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J Am Chem Soc. 2013;135:9723–9732. doi:10.1021/ja4014375.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Giddens J, Pincetic A, Lomino JV, Ravetch JV, Wang LX, Bjorkman PJ. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol. 2014;426:3166–3179. doi:10.1016/j.jmb.2014.07.006.
   PubMed Web of Science ®Google Scholar
• Barb AW, Prestegard JH. 2011. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol. 7:147–153. doi:10.1038/nchembio.511.
   PubMed Web of Science ®Google Scholar
• Barb AW, Meng L, Gao Z, Johnson RW, Moremen KW, Prestegard JH. 2012. NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry. 51:4618–4626. doi:10.1021/bi300319q.
   PubMed Web of Science ®Google Scholar
• Okbazghi SZ, More AS, White DR, Duan S, Shah IS, Joshi SB, Middaugh CR, Volkin DB, Tolbert TJ. Production, characterization, and biological evaluation of well-defined IgG1 Fc glycoforms as a model system for biosimilarity analysis. J Pharm Sci. 2016;105:559–574. doi:10.1016/j.xphs.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Subedi GP, Barb AW. 2016. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc gamma receptor. MAbs. 8:1512–1524. doi:10.1080/19420862.2016.1218586.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Nishimura M, Nagano M, Yagi H, Sasakawa H, Uchida K, Shitara K, Kato K. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta. 2006;1760:693–700. doi:10.1016/j.bbagen.2005.10.002.
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733–26740. doi:10.1074/jbc.M202069200.
   PubMed Web of Science ®Google Scholar
• Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry. 20;1981:2361–2370.
   PubMed Web of Science ®Google Scholar
• Lee HS, Im W. 2017. Effects of N-glycan composition on structure and dynamics of IgG1 Fc and their implications for antibody engineering. Sci Rep. 7:12659. doi:10.1038/s41598-017-12830-5.
   PubMed Web of Science ®Google Scholar
• Su C, Lua W-H, Ling W-L, Gan S. 2018. Allosteric effects between the antibody constant and variable regions: A study of IgA Fc mutations on antigen binding. Antibodies. 7:20. doi:10.3390/antib7020020.
   Web of Science ®Google Scholar
• Janda A, Casadevall A. 2010. Circular Dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure. Mol Immunol. 47:1421–1425. doi:10.1016/j.molimm.2010.02.018.
   PubMed Web of Science ®Google Scholar
• Janda A, Eryilmaz E, Nakouzi A, Cowburn D, Casadevall A. 2012. Variable region identical immunoglobulins differing in isotype express different paratopes. J Biol Chem. 287:35409–35417. doi:10.1074/jbc.M112.404483.
   PubMed Web of Science ®Google Scholar
• Correa A, Trajtenberg F, Obal G, Pritsch O, Dighiero G, Oppezzo P, Buschiazzo A. Structure of a human IgA1 Fab fragment at 1.55 A resolution: potential effect of the constant domains on antigen-affinity modulation. Acta Crystallogr D Biol Crystallogr. 2013;69:388–397. doi:10.1107/S0907444912048664.
   PubMedGoogle Scholar
• Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A. 2013;110:9019–9024. doi:10.1073/pnas.1301456110.
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Shikhman AR, Glass DD, Kangisser D, Cunningham MW, Greenspan NS. Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains. J Immunol. 150;1993:2231–2242.
   PubMed Web of Science ®Google Scholar
• Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, Mignogna G, Maras B, Colone M, Stringaro A, et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One. 2009;4:e5392. doi:10.1371/journal.pone.0005392.
   PubMed Web of Science ®Google Scholar
• Kato K, Matsunaga C, Odaka A, Yamato S, Takaha W, Shimada I, Arata Y. Carbon-13 NMR study of switch variant anti-dansyl antibodies: antigen binding and domain-domain interactions. Biochemistry. 1991;30:6604–6610.
   PubMed Web of Science ®Google Scholar
• Torres M, May R, Scharff MD, Casadevall A. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol. 174;2005:2132–2142.
   PubMed Web of Science ®Google Scholar
• Xia Y, Pawar RD, Nakouzi AS, Herlitz L, Broder A, Liu K, Goilav B, Fan M, Wang L, Li QZ, et al. The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies. J Autoimmun. 2012;39:398–411. doi:10.1016/j.jaut.2012.06.005.
   PubMed Web of Science ®Google Scholar
• Abboud N, Chow SK, Saylor C, Janda A, Ravetch JV, Scharff MD, Casadevall A. A requirement for FcgammaR in antibody-mediated bacterial toxin neutralization. J Exp Med. 2010;207:2395–2405. doi:10.1084/jem.20100995.
   PubMed Web of Science ®Google Scholar
• Ettayapuram Ramaprasad AS, Uddin S, Casas-Finet J, Jacobs DJ. 2017. Decomposing dynamical couplings in mutated scFv antibody fragments into stabilizing and destabilizing effects. J Am Chem Soc. 139:17508–17517. doi:10.1021/jacs.7b09268.
   PubMed Web of Science ®Google Scholar
• Perchiacca JM, Ladiwala ARA, Bhattacharya M, Tessier PM Structure-based design of conformation- and sequence-specific antibodies against amyloid beta. Proceedings of the National Academy of Sciences of the United States of America 2012; 109:84–89. doi:10.1073/pnas.1111232108
   Google Scholar
• Zhang M, Zheng J, Nussinov R, Ma B. 2018. Molecular recognition between Aβ-specific single-domain antibody and Aβ Misfolded aggregates. Antibodies. 7:25. doi:10.3390/antib7030025.
   Web of Science ®Google Scholar
• Crespi GA, Hermans SJ, Parker MW, Miles LA. 2015. Molecular basis for mid-region amyloid-beta capture by leading Alzheimer’s disease immunotherapies. Sci Rep. 5:9649. doi:10.1038/srep09649.
   PubMed Web of Science ®Google Scholar
• Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31;2003:3381–3385.
   PubMed Web of Science ®Google Scholar
• Kale L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, Krawetz N, Phillips J, Shinozaki A, Varadarajan K, Schulten K. NAMD2: greater scalability for parallel molecular dynamics. J Comput Phys. 1999;151:283–312. doi:10.1006/jcph.1999.6201.
   Web of Science ®Google Scholar
• MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B. 1998;102:3586–3616. doi:10.1021/jp973084f.
   PubMed Web of Science ®Google Scholar
• Ofran Y, Schlessinger A, Rost B. Automated identification of complementarity determining regions (CDRs) reveals peculiar characteristics of CDRs and B cell epitopes. J Immunol. 181;2008:6230–6235.
   PubMed Web of Science ®Google Scholar
• Pietal MJ, Tuszynska I, Bujnicki JM. 2007. PROTMAP2D: visualization, comparison and analysis of 2D maps of protein structure. Bioinformatics. 23:1429–1430. doi:10.1093/bioinformatics/btm124.
   PubMed Web of Science ®Google Scholar
• Lee MS, Feig M, Salsbury FR Jr., Brooks CL 3rd. 2003. New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations. J Comput Chem. 24:1348–1356. doi:10.1002/jcc.10272.
   PubMed Web of Science ®Google Scholar
• Ichiye T, Karplus M. 1991. Collective motions in proteins: a covariance analysis of atomic fluctuations in molecular dynamics and normal mode simulations. Proteins Struct Funct Bioinf. 11:205–217. doi:10.1002/prot.340110305.
   PubMed Web of Science ®Google Scholar
• Hünenberger P, Mark A, Van Gunsteren W. 1995. Fluctuation and cross-correlation analysis of protein motions observed in nanosecond molecular dynamics simulations. J Mol Biol. 252:492–503. doi:10.1006/jmbi.1995.0514.
   PubMed Web of Science ®Google Scholar
• Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell. 105;2001:115–126.
   PubMed Web of Science ®Google Scholar
• Tai K, Shen T, Börjesson U, Philippopoulos M, McCammon JA. 2001. Analysis of a 10-ns molecular dynamics simulation of mouse acetylcholinesterase. Biophys J. 81:715–724. doi:10.1016/S0006-3495(01)75736-0.
   PubMed Web of Science ®Google Scholar
• Glykos NM. 2006. Software news and updates carma: A molecular dynamics analysis program. J Comput Chem. 27:1765–1768. doi:10.1002/jcc.20482.
   PubMed Web of Science ®Google Scholar
• Eargle J, Luthey-Schulten Z. 2012. NetworkView: 3D display and analysis of protein· RNA interaction networks. Bioinformatics. 28:3000–3001. doi:10.1093/bioinformatics/bts546.
   PubMed Web of Science ®Google Scholar